DrugPatentWatch Database Preview

Par Pharm Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PAR PHARM INC, and when can generic versions of PAR PHARM INC drugs launch?

PAR PHARM INC has thirty-six approved drugs.

There is one US patent protecting PAR PHARM INC drugs. There are seven tentative approvals on PAR PHARM INC drugs.

There are nine patent family members on PAR PHARM INC drugs in eight countries and forty-nine supplementary protection certificates in twelve countries.

Summary for Par Pharm Inc

International Patents:	9
US Patents:	1
Tradenames:	33
Ingredients:	33
NDAs:	36

Drugs and US Patents for Par Pharm Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm Inc	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	070581-001	Oct 17, 1985	AB	RX	No	No
Par Pharm Inc	DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	206159-003	May 31, 2019	AB	RX	No	No
Par Pharm Inc	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	202842-001	Nov 30, 2016	AB	RX	No	No
Par Pharm Inc	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE	amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	206137-001	Oct 26, 2016	AB	RX	No	No
Par Pharm Inc	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	200812-003	Nov 10, 2011	AB	RX	No	No
Par Pharm Inc	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	078783-003	Sep 20, 2011	AB1	RX	No	No
Par Pharm Inc	TRAMADOL HYDROCHLORIDE	tramadol hydrochloride	TABLET, EXTENDED RELEASE;ORAL	078783-001	Nov 13, 2009	AB1	RX	No	No

Expired US Patents for Par Pharm Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	5,583,152
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	5,612,367
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	4,859,692
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	4,859,692
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	6,143,775
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-001	Sep 26, 1996	5,294,636
Par Pharm Inc	ACCOLATE	zafirlukast	TABLET;ORAL	020547-003	Sep 17, 1999	5,319,097

Paragraph IV (Patent) Challenges for PAR PHARM INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	10 mg and 20 mg		2008-02-29

International Patents for Par Pharm Inc Drugs

Country	Patent Number	Estimated Expiration
Canada	2605413
Japan	5378788
Japan	2008538560
South Korea	20080000660
Australia	2006240490
World Intellectual Property Organization (WIPO)	2006115626
European Patent Office	1948613

Supplementary Protection Certificates for Par Pharm Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0502314	SPC/GB11/010	United Kingdom		PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
0245997	SPC/GB00/005	United Kingdom		PRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129
1915993	C300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
2101777	93081	Luxembourg		PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
2101777	300813	Netherlands		PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
0199543	97C0031	Belgium		PRODUCT NAME: ZAFIRLUKAST; NAT. REGISTRATION NO/DATE: 624 S 295 F 3 19961216; FIRST REGISTRATION: IE PA 51/67/1 19960103
1507558	2012/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Par Form
• Par Pharm
• Par Pharm Inc
• Par Sterile Products